Olema Pharmaceuticals (OLMA) vs Prime Medicine (PRME)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Olema Pharmaceuticals (OLMA) has outperformed Prime Medicine (PRME) over the past year, losing 23.9% versus a loss of 33.6%. Prime Medicine is the larger company by market cap ($681.1 million vs $671.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | OLMA | PRME |
|---|---|---|
| Share price | $7.67 | $3.76 |
| Market cap | $671.11M | $681.07M |
| 1-day change | -3.40% | -3.72% |
| YTD return | -68.24% | +12.39% |
| 1-year return | -23.95% | -33.56% |
| 5-year return | -74.15% | — |
| EPS (TTM) | $-2.12 | $-1.07 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $36.26 | $6.65 |
| 52-week low | $6.65 | $2.67 |
| Distance from 52-week high | -78.85% | -43.53% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +375.88% | +89.35% |
| Average volume | 1.06M | 3.32M |
| Shares outstanding | 87.50M | 181.38M |
| Employees | 150 | 146 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Olema Pharmaceuticals
OLMA stock →Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic ER-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivotal Phase 3 clinical trial of palazestrant as a monotherapy in second/third-line ER+/HER2- metastatic breast cancer; and palazestrant with CDK4/6 inhibitors, a phosphatidylinositol 3 kinase alpha (PI3Ka) inhibitor alpelisib, a mechanistic target of rapamycin inhibitor, and a CDK4 inhibitor that is in Phase 1b/2 clinical trial for the treatment of ER+/HER2- advanced or metastatic breast cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 150 employees
About Prime Medicine
PRME stock →Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. Its lead therapeutic product candidate is PM359 for Chronic Granulomatous Disease, which is in Phase 1/2 clinical trial; PM577 for Wilson Disease, that is in preclinical studies; and PM647 to treat genetic disorder caused by mutations in the SERPINA1 gene, resulting in production of misfolded Z-AAT protein that accumulates in the liver and leads to hepatocellular injury, cirrhosis, and increased risk of hepatocellular carcinoma.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 146 employees
OLMA vs PRME FAQ
Which is bigger, Olema Pharmaceuticals or Prime Medicine?
Prime Medicine (PRME) is larger, with a market capitalization of $681.07M compared with $671.11M for Olema Pharmaceuticals (OLMA).
Which stock has performed better over the past year, OLMA or PRME?
OLMA returned -23.95% over the past 12 months, compared with -33.56% for PRME (price return, excluding dividends). Past performance does not predict future results.
Are Olema Pharmaceuticals and Prime Medicine in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Olema Pharmaceuticals and Biotechnology: Biological Products (No Diagnostic Substances) for Prime Medicine.